Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 4/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.43 |
| ▸ | ALPI | P09923 | 1/20 | 0.43 |
| ▸ | XIAP | P98170 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | RGS12 | O14924 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.40 |
| ▸ | THPO | P40225 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3504346 | 1.00 | SLC7A5 (0.43) | SLC7A5PKMPTGS1ALPIXIAP | |
| SCHEMBL22652556 | 0.86 | — | — | |
| SCHEMBL30531426 | 0.85 | SLC7A5 (0.40) | SLC7A5PKMPTGS1ALPIXIAP | |
| SCHEMBL30531466 | 0.85 | SLC7A5 (0.40) | SLC7A5PKMPTGS1ALPIXIAP | |
| SCHEMBL18567232 | 0.84 | ALPI (0.31) | SLC7A5PKMPTGS1ALPIXIAP | |
| SCHEMBL20877592 | 0.80 | KDM6B (0.36) | — | |
| SCHEMBL12153681 | 0.79 | APAF1 (0.33) | HSD17B10KDM4ERECQLALDH1A1POLB | |
| SCHEMBL25111145 | 0.78 | ITGB3 (0.51) | SLC7A5PKMPTGS1ALPIXIAP | |
| SCHEMBL4623688 | 0.76 | HDAC1 (0.31) | — | |
| SCHEMBL27293069 | 0.74 | SLC7A5 (0.53) | SLC7A5PKMPTGS1ALPIXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1687401-B1 | SITE-SPECIFIC INCORPORATION OF REDOX ACTIVE AMINO ACIDS INTO PROTEINS | SCRIPPS RESEARCH INST (US) | 2012-11-21 | — | — | EP | claimed |
| EP-1763535-B1 | POLYPEPTIDE LINKED WITH AN ORGANIC GROUP | JENNISSEN HERBERT P (DE) | 2008-01-23 | — | — | EP | claimed |
| US-12569443-B2 | Gastro-retentive drug delivery system | APET Holding B.V. (NL) | 2026-03-10 | — | — | US | disclosed |
| EP-4599695-A2 | LIQUID NUTRITIONAL COMPOSITION SUITABLE FOR MUSCLE FUNCTION | N.V. Nutricia (NL) | 2025-08-13 | — | — | EP | disclosed |
| EP-4307923-B1 | LIQUID NUTRITIONAL COMPOSITION SUITABLE FOR MUSCLE FUNCTION | NUTRICIA NV (NL) | 2025-06-25 | — | — | EP | disclosed |
| US-12178848-B2 | Methods and compositions for the treatment of exocrine pancreatic insufficiency | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-12-31 | — | — | US | disclosed |
| US-20240299490-A1 | LIQUID NUTRITIONAL COMPOSITION SUITABLE FOR MUSCLE FUNCTION | N.V. NUTRICIA (NL) | 2024-09-12 | — | — | US | disclosed |
| US-20240269215-A1 | NUTRITIONAL COMPOSITION FOR MUSCLE MASS, STRENGTH AND FUNCTION | N.V. NUTRICIA (NL) | 2024-08-15 | — | — | US | disclosed |
| US-20240216293-A1 | USE OF PERILLYL ALCOHOL TO ENHANCE LEVO-DOPA DELIVERY | UNIVERSITY OF SOUTHERN CALIFORNIA | 2024-07-04 | — | — | US | disclosed |
| US-20240209353-A1 | NADK2 INHIBITION IN CANCER AND FIBROTIC DISORDERS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2024-06-27 | — | — | US | disclosed |
| EP-4380381-A1 | NUTRITIONAL COMPOSITION FOR MUSCLE MASS, STRENGTH AND FUNCTION | N.V. Nutricia (NL) | 2024-06-12 | — | — | EP | disclosed |
| US-20020065274-A1 | METHODS OF USING NOVEL COMPOUNDS AS NEURO-PROTECTIVE AGENTS | PANETTA JILL ANN (US) | 2002-05-30 | — | — | US | disclosed |
| US-6380213-B1 | PHENYL OXAZOLES, THIAZOLES, OXAZOLINES, OXADIAZOLES AND BENZOXAZOLES | ELI LILLY AND COMPANY | 2002-04-30 | — | — | US | disclosed |
| US-20010027194-A1 | NOVEL COMPOUNDS USEFUL AS NEURO-PROTECTIVE AGENTS | ELI LILLY AND COMPANY | 2001-10-04 | — | — | US | disclosed |
| US-6166216-A | Compounds useful as neuro-protective agents | ELI LILLY AND COMPANY (US) | 2000-12-26 | — | — | US | disclosed |
| US-6156748-A | Compounds useful as neuro-protective agents | ELI LILLY AND COMPANY (US) | 2000-12-05 | — | — | US | disclosed |
| WO-1999018091-A1 | NOVEL COMPOUNDS USEFUL AS NEURO-PROTECTIVE AGENTS | ELI LILLY AND COMPANY (US) | 1999-04-15 | — | — | WO | disclosed |
| EP-0908454-A2 | Oxazoles, thiazoles, oxazolines, oxadiazoles and benzoxazoles useful as neuro-protective agents | ELI LILLY AND COMPANY (US) | 1999-04-14 | — | — | EP | disclosed |
| US-5476842-A | Method and compositions for treating tumors having high tyrosinase activity | CO ENZYME TECHNOLOGY LTD. (US) | 1995-12-19 | — | — | US | disclosed |
| EP-0657469-A1 | L-Selectin cleavage site, methods of diagnosis and usage thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 1995-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12569443-B2 | Gastro-retentive drug delivery system | GYS2, ABCB11, GYS1 | SLC7A5 49/4885PKM 555/4885PTGS1 73/4885 |
| US-20240216293-A1 | USE OF PERILLYL ALCOHOL TO ENHANCE LEVO-DOPA DELIVERY | SNCA, SLC18A2, SLC18A3 | SLC7A5 345/4885PKM 2021/4885PTGS1 3587/4885 |
| US-20010027194-A1 | NOVEL COMPOUNDS USEFUL AS NEURO-PROTECTIVE AGENTS | NLN, PRDX5, TXN2 | SLC7A5 2964/4885PKM 2604/4885PTGS1 380/4885 |
| US-20020065274-A1 | METHODS OF USING NOVEL COMPOUNDS AS NEURO-PROTECTIVE AGENTS | NLN, GAP43, TXN2 | SLC7A5 4054/4885PKM 2508/4885PTGS1 453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.